Does the media refer more to NAMS or VSTM?

In the previous week, Verastem had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 11 mentions for Verastem and 9 mentions for NewAmsterdam Pharma. Verastem's average media sentiment score of 0.46 beat NewAmsterdam Pharma's score of 0.25 indicating that Verastem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Verastem 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ZLAB or VSTM?

Zai Lab has higher revenue and earnings than Verastem. Zai Lab is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 6.18 -$175.54M -$1.71 N/A Verastem $30.91M 24.55 -$209.47M -$2.66 N/A

Is ZLAB or VSTM more profitable?

Zai Lab has a net margin of -41.86% compared to Verastem's net margin of -231.59%. Zai Lab's return on equity of -27.43% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -41.86% -27.43% -16.72% Verastem -231.59% -467.49% -94.54%

Does the media refer more to ZLAB or VSTM?

In the previous week, Verastem had 7 more articles in the media than Zai Lab. MarketBeat recorded 11 mentions for Verastem and 4 mentions for Zai Lab. Verastem's average media sentiment score of 0.46 beat Zai Lab's score of 0.26 indicating that Verastem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Verastem 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VSTM or CLDX?

In the previous week, Verastem had 4 more articles in the media than Celldex Therapeutics. MarketBeat recorded 11 mentions for Verastem and 7 mentions for Celldex Therapeutics. Verastem's average media sentiment score of 0.46 beat Celldex Therapeutics' score of 0.31 indicating that Verastem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celldex Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, VSTM or BEAM?

Beam Therapeutics has higher revenue and earnings than Verastem. Beam Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 24.55 -$209.47M -$2.66 N/A Beam Therapeutics $139.74M 19.00 -$79.99M -$0.86 N/A

Is VSTM or BEAM more profitable?

Beam Therapeutics has a net margin of -54.75% compared to Verastem's net margin of -231.59%. Beam Therapeutics' return on equity of -30.71% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -231.59% -467.49% -94.54% Beam Therapeutics -54.75% -30.71% -24.07%

Does the media prefer VSTM or BEAM?

In the previous week, Verastem had 3 more articles in the media than Beam Therapeutics. MarketBeat recorded 11 mentions for Verastem and 8 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.57 beat Verastem's score of 0.46 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, VSTM or IRON?

Verastem has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 24.55 -$209.47M -$2.66 N/A Disc Medicine N/A N/A -$212.18M -$6.58 N/A

Is VSTM or IRON more profitable?

Disc Medicine has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Disc Medicine's return on equity of -37.17% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -231.59% -467.49% -94.54% Disc Medicine N/A -37.17% -33.65%

Does the media refer more to VSTM or IRON?

In the previous week, Verastem had 9 more articles in the media than Disc Medicine. MarketBeat recorded 11 mentions for Verastem and 2 mentions for Disc Medicine. Verastem's average media sentiment score of 0.46 beat Disc Medicine's score of 0.36 indicating that Verastem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Disc Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Verastem (VSTM) Competitors

$8.38 +0.27 (+3.33%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$8.46 +0.08 (+0.91%)

As of 10/9/2026 07:59 PM Eastern

Compare

VSTM vs. NAMS, ZLAB, CLDX, BEAM, and IRON

Should you buy Verastem stock or one of its competitors? Verastem's main competitors and comparable companies include NewAmsterdam Pharma (NAMS), Zai Lab (ZLAB), Celldex Therapeutics (CLDX), Beam Therapeutics (BEAM), and Disc Medicine (IRON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Verastem compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Verastem (NASDAQ:VSTM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

NewAmsterdam Pharma has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, Verastem has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

In the previous week, Verastem had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 11 mentions for Verastem and 9 mentions for NewAmsterdam Pharma. Verastem's average media sentiment score of 0.46 beat NewAmsterdam Pharma's score of 0.25 indicating that Verastem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verastem	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 1.9% of Verastem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Verastem has a net margin of -231.59% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Verastem	-231.59%	-467.49%	-94.54%

NewAmsterdam Pharma has higher earnings, but lower revenue than Verastem. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	114.65	-$203.82M	-$2.16	N/A
Verastem	$30.91M	24.55	-$209.47M	-$2.66	N/A

NewAmsterdam Pharma currently has a consensus price target of $49.00, indicating a potential upside of 127.06%. Verastem has a consensus price target of $13.83, indicating a potential upside of 65.08%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe NewAmsterdam Pharma is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Verastem	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

NewAmsterdam Pharma beats Verastem on 10 of the 16 factors compared between the two stocks.

How does Verastem compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Verastem (NASDAQ:VSTM) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Verastem had 7 more articles in the media than Zai Lab. MarketBeat recorded 11 mentions for Verastem and 4 mentions for Zai Lab. Verastem's average media sentiment score of 0.46 beat Zai Lab's score of 0.26 indicating that Verastem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Verastem	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zai Lab has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Verastem has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Zai Lab currently has a consensus target price of $37.25, indicating a potential upside of 49.06%. Verastem has a consensus target price of $13.83, indicating a potential upside of 65.08%. Given Verastem's stronger consensus rating and higher probable upside, analysts clearly believe Verastem is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Verastem	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Zai Lab has higher revenue and earnings than Verastem. Zai Lab is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.18	-$175.54M	-$1.71	N/A
Verastem	$30.91M	24.55	-$209.47M	-$2.66	N/A

Zai Lab has a net margin of -41.86% compared to Verastem's net margin of -231.59%. Zai Lab's return on equity of -27.43% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Verastem	-231.59%	-467.49%	-94.54%

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Comparatively, 1.9% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Zai Lab beats Verastem on 9 of the 17 factors compared between the two stocks.

How does Verastem compare to Celldex Therapeutics?

Verastem (NASDAQ:VSTM) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Celldex Therapeutics has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Celldex Therapeutics' return on equity of -52.35% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Verastem has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Verastem has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	24.55	-$209.47M	-$2.66	N/A
Celldex Therapeutics	$1.54M	1,524.20	-$258.76M	-$4.35	N/A

In the previous week, Verastem had 4 more articles in the media than Celldex Therapeutics. MarketBeat recorded 11 mentions for Verastem and 7 mentions for Celldex Therapeutics. Verastem's average media sentiment score of 0.46 beat Celldex Therapeutics' score of 0.31 indicating that Verastem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celldex Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

88.4% of Verastem shares are owned by institutional investors. 1.9% of Verastem shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Verastem currently has a consensus target price of $13.83, indicating a potential upside of 65.08%. Celldex Therapeutics has a consensus target price of $61.92, indicating a potential upside of 107.17%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Celldex Therapeutics beats Verastem on 10 of the 17 factors compared between the two stocks.

How does Verastem compare to Beam Therapeutics?

Verastem (NASDAQ:VSTM) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Beam Therapeutics has a net margin of -54.75% compared to Verastem's net margin of -231.59%. Beam Therapeutics' return on equity of -30.71% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

In the previous week, Verastem had 3 more articles in the media than Beam Therapeutics. MarketBeat recorded 11 mentions for Verastem and 8 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.57 beat Verastem's score of 0.46 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Verastem presently has a consensus price target of $13.83, indicating a potential upside of 65.08%. Beam Therapeutics has a consensus price target of $50.10, indicating a potential upside of 94.94%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Verastem has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.2, suggesting that its stock price is 120% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Verastem. Beam Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	24.55	-$209.47M	-$2.66	N/A
Beam Therapeutics	$139.74M	19.00	-$79.99M	-$0.86	N/A

88.4% of Verastem shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 1.9% of Verastem shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Beam Therapeutics beats Verastem on 12 of the 16 factors compared between the two stocks.

How does Verastem compare to Disc Medicine?

Verastem (NASDAQ:VSTM) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Disc Medicine has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Disc Medicine's return on equity of -37.17% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
Disc Medicine	N/A	-37.17%	-33.65%

Verastem has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	24.55	-$209.47M	-$2.66	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Verastem presently has a consensus target price of $13.83, suggesting a potential upside of 65.08%. Disc Medicine has a consensus target price of $110.18, suggesting a potential upside of 77.54%. Given Disc Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Disc Medicine is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Verastem had 9 more articles in the media than Disc Medicine. MarketBeat recorded 11 mentions for Verastem and 2 mentions for Disc Medicine. Verastem's average media sentiment score of 0.46 beat Disc Medicine's score of 0.36 indicating that Verastem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verastem has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

88.4% of Verastem shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Disc Medicine beats Verastem on 8 of the 15 factors compared between the two stocks.

Get Verastem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VSTM vs. The Competition

Export

Metric	Verastem	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$758.92M	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-3.15	13.55	275.01	26.14
Price / Sales	24.55	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	11.32	17.17	11.22	6.33
Net Income	-$209.47M	-$22.69M	$3.50B	$382.15M
7 Day Performance	8.83%	-1.34%	-0.89%	-1.40%
1 Month Performance	14.48%	-8.04%	-4.02%	-3.35%
1 Year Performance	-2.22%	14.18%	7.13%	1.49%

Verastem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VSTM Verastem	3.5741 of 5 stars	$8.38 +3.3%	$13.83 +65.1%	-2.2%	$758.92M	$30.91M	N/A	102	Analyst Forecast
NAMS NewAmsterdam Pharma	3.4909 of 5 stars	$22.80 -1.7%	$49.00 +114.9%	-41.8%	$2.77B	$22.50M	N/A	100
ZLAB Zai Lab	2.9432 of 5 stars	$25.62 +5.3%	$37.25 +45.4%	-17.4%	$2.77B	$460.16M	N/A	1,784	Analyst Forecast
CLDX Celldex Therapeutics	2.7001 of 5 stars	$32.59 +3.0%	$61.92 +90.0%	+11.7%	$2.56B	$158K	N/A	198
BEAM Beam Therapeutics	2.1615 of 5 stars	$25.67 +4.8%	$49.00 +90.9%	-2.4%	$2.53B	$156.04M	N/A	540

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VSTM) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verastem (VSTM) Competitors

VSTM vs. NAMS, ZLAB, CLDX, BEAM, and IRON

How does Verastem compare to NewAmsterdam Pharma?

Summary

How does Verastem compare to Zai Lab?

Summary

How does Verastem compare to Celldex Therapeutics?

Summary

How does Verastem compare to Beam Therapeutics?

Summary

How does Verastem compare to Disc Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verastem (VSTM) Competitors

VSTM vs. NAMS, ZLAB, CLDX, BEAM, and IRON

How does Verastem compare to NewAmsterdam Pharma?

Which has more risk & volatility, NAMS or VSTM?

Does the media refer more to NAMS or VSTM?

Do institutionals and insiders believe in NAMS or VSTM?

Is NAMS or VSTM more profitable?

Which has higher earnings & valuation, NAMS or VSTM?

Do analysts prefer NAMS or VSTM?

Summary

How does Verastem compare to Zai Lab?

Does the media refer more to ZLAB or VSTM?

Which has more volatility and risk, ZLAB or VSTM?

Do analysts recommend ZLAB or VSTM?

Which has stronger valuation & earnings, ZLAB or VSTM?

Is ZLAB or VSTM more profitable?

Do institutionals and insiders have more ownership in ZLAB or VSTM?

Summary

How does Verastem compare to Celldex Therapeutics?

Is VSTM or CLDX more profitable?

Which has more volatility & risk, VSTM or CLDX?

Which has preferable earnings and valuation, VSTM or CLDX?

Does the media prefer VSTM or CLDX?

Do institutionals & insiders have more ownership in VSTM or CLDX?

Do analysts recommend VSTM or CLDX?

Summary

How does Verastem compare to Beam Therapeutics?

Is VSTM or BEAM more profitable?

Does the media prefer VSTM or BEAM?

Do analysts prefer VSTM or BEAM?

Which has more risk & volatility, VSTM or BEAM?

Which has preferable valuation and earnings, VSTM or BEAM?

Do institutionals & insiders believe in VSTM or BEAM?

Summary

How does Verastem compare to Disc Medicine?

Is VSTM or IRON more profitable?

Which has preferable earnings and valuation, VSTM or IRON?

Do analysts rate VSTM or IRON?

Does the media refer more to VSTM or IRON?

Which has more volatility and risk, VSTM or IRON?

Do institutionals and insiders believe in VSTM or IRON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools